ReviewJournal of immunology research2026
Piplartine as an Innovative Natural Product With Dual Antiparasitic and Immunomodulatory Actions.
Review in Journal of immunology research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Andrographolide as a Promising Diterpenoid Scaffold Against the Neurotropic NematodePharmaceuticals (Basel, Switzerland) · 2026Article
- Article
- Molecular biology of vascular bioenergetics rewiring: Mitochondrial protective mechanisms of Piper retrofractum in hypertension and oxidative injury.Molecular biology reports · 2026Review
- Spathulenol, a Sesquiterpene fromACS omega · 2026Article
- Piplartine as an Innovative Natural Product With Dual Antiparasitic and Immunomodulatory Actions.Journal of immunology research · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Neglected tropical diseases (NTDs) remain a major global health burden, disproportionately affecting low- and middle-income regions and demanding innovative therapeutic strategies. This review summarizes current evidence on piplartine (piperlongumine), a naturally occurring amide from Piper species with broad antiparasitic and immunomodulatory properties. Studies on Schistosoma mansoni, Angiostrongylus cantonensis, Leishmania spp., Trypanosoma cruzi, Trypanosoma brucei, Plasmodium falciparum, and Toxoplasma gondii demonstrate potent activity at micromolar levels, associated with disruption of parasite redox homeostasis. In host immune cells, piplartine modulates NF-κB and Nrf2 signaling, inhibits the immunoproteasome, and promotes antioxidant and anti-inflammatory responses. These dual properties suggest that piplartine may influence both parasite survival and host immunopathology through redox-sensitive mechanisms, although direct cause-effect relationships during parasitic infection remain to be experimentally established. The compound's favorable drug-likeness, oral bioavailability, and selective toxicity profile highlight its potential as a multitarget scaffold for the development of next-generation therapeutics against neglected tropical and immune-related diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.